Plasma p-tau217 and Aβ42/40 as markers of Aβ pathology in the Lewy body continuum.

ABSTRACT:

Introduction

This study evaluated whether plasma phosphorylated tau-217 (p-tau217), amyloid beta (Aβ)42/40, and their combination could serve as biomarkers of Aβ co-pathology across the Lewy body continuum, where Aβ is frequently observed from prodromal to symptomatic stages.

Methods

Individuals with dementia with Lewy bodies (DLB), Parkinson's disease (PD), and their shared prodromal stage, isolated rapid eye movement (REM) sleep behavior disorder (iRBD) underwent plasma sampling, Aβ-PET, and cognitive testing.

Results

Higher plasma p-tau217, lower Aβ42/40, and their interaction were associated with greater Aβ-PET uptake. Individuals with higher-than-median p-tau217 and lower-than-median Aβ42/40 showed the highest Aβ burden. Both biomarkers predicted Aβ-PET positivit

SUBMITTER: Woo KA 

PROVIDER: S-EPMC12515049 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature